Abstract: The pharmaceutical use of nitroglycerin, which is also designated as glycerol trinitrate or, chemically, as 1,2,3-propanetriol trinitrate, in a transdermal application form prevents undesired labour in pregnant mammals. The pharmaceutical use prevents premature labour.
Type:
Grant
Filed:
July 1, 1997
Date of Patent:
October 6, 1998
Assignee:
Schwarz Pharma AG
Inventors:
Hans-Michael Wolff, Dietrich Schacht, Martin Feelisch, Bruce Ramsay, John Francis Martin, Christoph Christopher Lees, Adam Julian De Belder
Abstract: A method of preventing renal failure or dysfunction caused by medical tests which utilize contrast media by administering, preferably by intravenous infusion or injection, a prostaglandin selected from PGE.sub.1, PGE.sub.2, PGI.sub.2 or an analog or pharmaceutically acceptable salt thereof and preferably in a form of a complex with .alpha.-cyclodextrin, to a patient at risk, for example, a diabetic.
Type:
Grant
Filed:
November 28, 1995
Date of Patent:
September 15, 1998
Assignee:
Schwarz Pharma, Inc.
Inventors:
Henry T. Stratton, Tammy K. Antonucci, Erwin Schollmayer
Abstract: A hydrophilic aqueous pump spray composition for treating angina pectoris comprising 0.15 to 0.50 weight/% of nitroglycerin, 24.50 to 24.85 weight/% of ethanol, 32.00 weight/% of 1,2-propyleneglycol and 43.00 weight/% of purified water and having a pH of 3 to 6; a method of producing the composition; and, a product comprising a container having the composition as a solution therein and provided with a dosage dispensing pump.
Abstract: The invention concerns a kit for the preparation of an emulsion containing prostaglandin E.sub.1, a method of preparing the emulsion and a method of preparing the emulsion composition contained in the kit. The emulsion prepared using this kit is suitable for parenteral application.
Type:
Grant
Filed:
September 21, 1995
Date of Patent:
October 28, 1997
Assignee:
Schwarz Pharma AG
Inventors:
Andreas Schutz, Hans-Jurgen Mika, Frank Sievert
Abstract: The invention relates to novel nitrates containing a disulphide group, and to processes for their preparation. The compounds can be used for the therapy of disorders of the cardiovascular system.
Type:
Grant
Filed:
December 5, 1995
Date of Patent:
August 26, 1997
Assignee:
Schwarz Pharma AG
Inventors:
Martin Feelisch, Hilmar Bokens, Jochen Lehmann, Claus Meese, Klaus Sandrock
Abstract: A method for the production of microcapsules embedded with pharmaceuticals, peptides, proteins, enzymes and vaccines, which uses biodegradable solvents, and microcapsules free of toxic residual solvents is described. The microcapsules are obtained by spraying of a solution, suspension or water-in-oil dispersion of active materials and biodegradable polymers.
Abstract: A device for producing a micro connection element 24, 30, the device comprising a cylindrical outer sleeve 1, a cylindrical central element 2 arranged coaxially in the outer sleeve 1, a plurality of cylindrical spacers 3 arranged between the outer sleeve 1 and the central element 2; the spacers 3 respectively arranged between two neighboring assembly elements 4 which are in contact with the neighboring spacers 3, the central element 2 and the outer sleeve 1; the assembly elements 4 can be microplug pins having a length such that they extend out of the arrangement comprising outer sleeve 1, central element 2 and spacers 3 so that the pins can support sleeves for making a microcoupling or female connection element, or the assembly elements 4 can be bushes into which microplug pins can be inserted, with a sleeve being joined to the outer end of each pin for receiving an electric wire, to thereby make a microplug or male connector; the microcoupling and microplug can be used on the ends of an electric supply lead
Abstract: The invention relates to a lyophilized emulsion composition which contains an active substance and which can be redispersed with water to give the original emulsion, and to a process for the preparation thereof.The redispersed emulsion is suitable for parenteral use.
Type:
Grant
Filed:
June 23, 1995
Date of Patent:
March 18, 1997
Assignee:
Schwarz Pharma AG
Inventors:
Andreas Schutz, Hans-Jurgen Mika, Frank Sievert, Bernhard Emschermann
Abstract: A method of preparing a patch for the controlled release of readily available volatile active substances to the skin is disclosed. The patch comprises a back layer, and, bonded to the back layer, a water-insoluble adhesive film consisting of a pressure-sensitive fusion adhesive, plus a detachable film covering the adhesive film. The pressure-sensitive fusion adhesive contains a triple-block copolymer of polystyrene block copoly(ethylene/butylene) block polystyrene at a concentration of 10 to 80% by wt., and an active substance at a concentration of 2.5 to 25% by weight, which is a readily volatile liquid at the temperature at which the adhesive bonds.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 18, 1997
Assignee:
Schwarz Pharma AG
Inventors:
Hans P. Merkle, Klaus Nagels, Dietrich Schacht, Hans-Michael Wolff
Abstract: The invention concerns a patch for the controlled release of readily available volatile active substances to the skin, the patch comprising a back layer and, bonded to it, a water-insoluble adhesive film consisting of a pressure-sensitive fusion adhesive, plus a detachable film covering the adhesive film. The patch is characterized in that the pressure-sensitive fusion adhesive contains a triple-block copolymer of polystyrene block copoly(ethylene/butylene) block polystyrene (SEBS) at a concentration of 10 to 80% by wt., and an active substance which, at the temperature at which the adhesive bonds, is a readily volatile liquid, and which is present at a concentration of 2.5 to 25% by wt.
Type:
Grant
Filed:
February 27, 1995
Date of Patent:
June 18, 1996
Assignee:
Schwarz Pharma AG
Inventors:
Hans P. Merkle, Klaus Nagels, Dietrich Schacht, Hans-Michael Wolff
Abstract: The invention relates to a dermal plaster for the transdermal provision of nitroglycerin comprising a carrier film and a removable protective film and an adhesive mass containing nitroglycerine on the basis of a cross-linked acrylate-vinyl acetate copolymer in which the monomer mix used for polymerization consists essentially of 21 to 40% wt. vinyl acetate, 55 to 70% wt. of an acrylic acid C2-8 alkyl ester and 3 to 10% wt. of an acrylic acid C2-4 hydroxyalkyl ester and which is cross-linked by heating and the removal of any solvents present after the addition of a cross-linking agent and the nitroglycerin.
Abstract: Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture. Pharmaceutical preparation to be administered orally with controlled release of active substance, containing a nucleus which itself consists at least of one pharmacologically active substance, or a nucleus of physiologically safe material which is enveloped by an active substance layer, containing at least one pharmacologically active substance, if needed, a first membrane, then an acid layer consisting at least of a physiologically safe acid and then a compound membrane consisting of a pH sensitive polymer and an insoluble polymer, as well as methods for its manufacture. The pharmaceutical preparation is applicable to all claimed types of medicine and to the therapy of illnesses.
Type:
Grant
Filed:
April 29, 1994
Date of Patent:
December 5, 1995
Assignee:
Schwarz Pharma AG
Inventors:
Karin Klokkers-Bethke, Wilfried Fischer
Abstract: Delayed release pharmaceutical preparations include a solvent free, solidified melt granulate of a pharmaceutical ingredient in admixture with a meltable auxiliary substance which is soluble in the pharmaceutical ingredient at elevated temperatures.
Type:
Grant
Filed:
April 7, 1993
Date of Patent:
September 26, 1995
Assignee:
Schwarz Pharma AG
Inventors:
Ulrich Munch, Hans-Jurgen Mika, Bernhard Emschermann, Rainer Schmidt, Bernhard Sczepanik
Abstract: New organic nitrate compounds, formed by condensing a nitrato alkanoic acid with a sulfur-containing amino acid or peptide, which prevent nitrate tolerance or overcome existing tolerance and which are useful for the treatment of cardiac diseases including circulatory diseases, high blood pressure, cardiac insufficiency and for dilating the peripheral vessels.
Type:
Grant
Filed:
September 7, 1993
Date of Patent:
June 27, 1995
Assignee:
Schwarz Pharma AG
Inventors:
Klaus Sandrock, Joachim Hutter, Eike Noack
Abstract: The invention concerns a method for the production of microscopic particles made of hydrolytically decomposable polymers, in particular copolymers, and containing active substances, using fluid gas with a uniform particle-size distribution and by the addition of biologically compatible amino acids. The microscopic particles produced by this method can be used as drugs for the treatment of humans or animals.
Type:
Grant
Filed:
June 22, 1993
Date of Patent:
June 13, 1995
Assignee:
Schwarz Pharma AG
Inventors:
Elke Gorissen, Heike Biskup, Hannelore Schneider
Abstract: A device for producing a micro connection element 24, 30, the device comprising a cylindrical outer sleeve 1, a cylindrical central element 2 arranged coaxially in the outer sleeve 1, a plurality of cylindrical spacers 3 arranged between the outer sleeve 1 and the central element 2; the spacers 3 respectively arranged between two neighboring assembly elements 4 which are in contact with the neighboring spacers 3, the central element 2 and the outer sleeve 1; the assembly elements 4 can be microplug pins having a length such that they extend out of the arrangement comprising outer sleeve 1, central element 2 and spacers 3 so that the pins can support sleeves for making a microcoupling or female connection element, or the assembly elements 4 can be bushes into which microplug pins can be inserted, with a sleeve being joined to the outer end of each pin for receiving an electric wire, to thereby make a microplug or male connector; the microcoupling and microplug can be used on the ends of an electric supply lead
Abstract: The present invention relates to active substance plasters for the controlled release of active substances to the skin consisting of a backing layer, an adhesive film connected therewith which film is water-soluble and consists of pressure-sensitive adhesive which comprises water-swellable polymers and in which the active substance is at least partially soluble, and of a removable protective layer covering the adhesive film, in which plasters the pressure-sensitive adhesive is based on homo and/or copolymers with at least one derivative of the acrylic or methacrylic acid, and which comprise as active substances, partially or completely dissolved in the adhesive, at a concentration of 0.5 to 10.0%-wt estrogens and their pharmaceutically acceptable derivatives alone or in combination with gestagens.
Abstract: A pharmaceutical aerosol spray for treating an angina attack including a container having a liquid composition therein comprising 0.1 to 2 weight percent of nitroglycerin, 2 to 60 weight percent of ethanol, 2 to 60 weight percent of propylene glycol, 10 to 50 weight percent of dichlorodifluoromethane and 30 to 70 weight percent of dichlorotetrafluoroethane, the container having a valve assembly sealed to the container around an opening in the container by a sealant material which has a nitroglycerin absorption value less than 10 mg/1 g of sealant material.
Abstract: A device for producing a micro connection element 24, 30, the device comprising a cylindrical outer sleeve 1, a cylindrical central element 2 arranged coaxially in the outer sleeve 1, a plurality of cylindrical spacers 3 arranged between the outer sleeve 1 and the central element 2; the spacers 3 respectively arranged between two neighboring assembly elements 4 which are in contact with the neighboring spacers 3, the central element 2 and the outer sleeve 1; the assembly elements 4 can be microplug pins having a length such that they extend out of the arrangement comprising outer sleeve 1, central element 2 and spacers 3 so that the pins can support sleeves for making a microcoupling or female connection element, or the assembly elements 4 can be bushes into which microplug pins can be inserted, with a sleeve being joined to the outer end of each pin for receiving an electric wire, to thereby make a microplug or male connector; the microcoupling and microplug can be used on the ends of an electric supply lead
Abstract: New organic nitrate compounds, formed by condensing a nitrato alkanoic acid with a sulfur-containing amino acid or peptide followed by the reaction of the resulting product with an amino acid, N-acylamino acid, peptide or an N-acyl peptide to produce a thio ester thereof, which prevent nitrate tolerance or overcome existing tolerance and which are useful for the treatment of cardiac diseases including circulatory diseases, coronary dilation, high blood pressure, cardiac insufficiency and for dilating the peripheral vessels.
Type:
Grant
Filed:
April 5, 1991
Date of Patent:
February 8, 1994
Assignee:
Schwarz Pharma AG
Inventors:
Klaus Sandrock, Eike Noack, Edgar Fritschi, Ralf Kanzler, Martin Feelisch